Following the release of the Ministry of Transportation & Infrastructure independent review of the George Massey Crossing yesterday, Richmond’s largest business association is expressing disappointment as the project goes back to square one. Richmond Chamber of Commerce Chair Barbara Tinson says that Richmond businesses are losing good employees because of the congestion issues at the Massey crossing. After Monday’s announcement, the Chamber fears that “whatever is finally built will be at or near capacity when it opens”.

Also chiming in on the disappointment is Clint Mahlman, President & Chief Operating Officer of London Drugs. In a release sent out yesterday, Mahlman said that the government’s lack of action on the Massey Crossing is forcing London Drugs to consider moving their head office and distribution centre, currently located in Richmond, to another area without the same congestion issues.

Guest: Barbara Tinson

Chair of the Richmond Chamber of Commerce

 

Guest: Clint Mahlman

President & Chief Operating Officer of London Drugs

Following the release of the Ministry of Transportation & Infrastructure independent review of the George Massey Crossing yesterday, Richmond’s largest business association is expressing disappointment as the project goes back to square one. Richmond Chamber of Commerce Chair Barbara Tinson says that Richmond businesses are losing good employees because of the congestion issues at the Massey crossing. After Monday’s announcement, the Chamber fears that “whatever is finally built will be at or near capacity when it opens”.


Also chiming in on the disappointment is Clint Mahlman, President & Chief Operating Officer of London Drugs. In a release sent out yesterday, Mahlman said that the government’s lack of action on the Massey Crossing is forcing London Drugs to consider moving their head office and distribution centre, currently located in Richmond, to another area without the same congestion issues.


Guest: Barbara Tinson


Chair of the Richmond Chamber of Commerce


 


Guest: Clint Mahlman


President & Chief Operating Officer of London Drugs